Morgan Stanley India Company Pvt Ltd (”Manager to the Offer”) on behalf of Fresenius Kabi (Singapore) Pte Ltd (”Acquirer”) & Fresenius Kabi Austria GmbH, Fresenius SE and Fresenius Finance BV (”Persons Acting in Concert”/ “PACs”) has issued this Public Announcement (”PA”) to the Equity shareholders of Dabur Pharma Ltd (”Target Company”), in compliance with Regulations 10 & 12 of the Securities & Exchange Board of India (Substantial Acquisition of Shares & Takeovers) Regulations, 1997 and subsequent amendments thereto (the “SEBI (SAST) Regulations”).

The Offer

This offer is made to all shareholders of the Target company, except to the parties to the Share Purchase Agreements, to acquire upto 3,13,41,260 fully paid-up equity shares of face value Rs 1 each of the Target Company (”Offer shares”) forming 20% of the Emerging voting Capital of the Target Company. The Offer is being made at a price of Rs 76.50 (Rupees seventy six and fifty paise only) for each full paid-up share (”Offer Price”) to be paid in cash in accordance with the SEBI (SAST) Regulations, and subject to the terms & conditions mentioned in the PA and as will be set out in the Letter of Offer in relation to the Offer (”Letter of Offer”). The Offer size is reckoned on the Emerging Voting Capital in terms of Regulations 21(1) and 21(5) of the SEBI (SAST) Regulations.

Schedule of Activities:

Specified Date - May 02, 2008

Date of Opening of the Offer - June 13, 2008

Date of Closing of the Offer - July 03, 2008